Dr. Massengill is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
900 NW 17th St
Miami, FL 33136Phone+1 305-326-6000
Education & Training
University of Illinois College of Medicine at ChicagoResidency, Ophthalmology, 2020 - 2024
University of Florida College of MedicineClass of 2016
Certifications & Licensure
FL State Medical License 2024 - 2026
IL State Medical License 2020 - 2024
Publications & Presentations
PubMed
- 228 citationsHDAC inhibitors enhance T cell chemokine expression and augment response to PD-1 immunotherapy in lung adenocarcinomaHong Zheng, Weipeng Zhao, Cihui Yan, Crystina C. Watson, Michael Massengill
Clinical Cancer Research. 2016-08-15 - 85 citationsLung tumor NF-κB signaling promotes T cell-mediated immune surveillance.Emily L. Hopewell, Weipeng Zhao, William J. Fulp, Crystina C. Bronk, Alexis S. Lopez
The Journal of Clinical Investigation. 2013-06-03 - 26 citationsA cell penetrating peptide from SOCS-1 prevents ocular damage in experimental autoimmune uveitis.Chulbul M. I. Ahmed, Michael T. Massengill, Emily E. Brown, Cristhian J Ildefonso, Howard M. Johnson
Experimental Eye Research. 2018-12-01
Journal Articles
- Clinically Relevant Outcome Measures for the I307N Rhodopsin Mouse: A Model of Inducible Autosomal Dominant Retinitis PigmentosaMichael Massengill, MD, Investigative Ophthalmology and Visual Science
- Mutation-Independent Rhodopsin Gene Therapy by Knockdown and Replacement with a Single AAV VectorMichael T Massengill, Samuel G Jacobson, Proceedings of the National Academy of Sciences
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
